On 19 November 2018, orphan designation (EU/3/18/2081) was granted by the European Commission to Pharma Gateway AB, Sweden, for 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (also known as AG10) for the treatment of ATTR amyloidosis.
|Disease / condition||
Treatment of ATTR amyloidosis
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;